POC

Central bank digital currency and monetary policy implementation

Retrieved on: 
Thursday, April 18, 2024
E41, Central bank digital currency, Atlantic Council, Research Papers in Economics, Remuneration, Norges Bank, People's Bank of China, Policy, Central Bank of Myanmar, Bank for International Settlements, Blog, Financial innovation, Sveriges Riksbank, Bank of Canada, Mechanics, Journal of Monetary Economics, Insurance, Bank of England, E42, Corridor, Quarterly Journal of Economics, Report card, Frankfurt, Appetite, American Economic Association, Digital rupee, Rosolin, RBI, PDF, Private, ECB, Committee, Inden, North Rhine-Westphalia, Bank, Canadian International Council, Social science, JEL, JMD, ECCB, Digital, Journal, Research, POC, European Central Bank, ENaira, M.A, Monetary economics, Section 5, Government, ISSN, The, Central bank, Finance, Buffer, Parliament, CBN, EONIA, Asset, ATM, Risk, International Monetary Fund, Interbank, Section 4, Ministry, Press release, Section 3, Human, Waterfall, Cryptocurrency, Economy, Swiss National Bank, PIB, Section 2, Conference, Reserve Bank, Reserve Bank of India, GBP, Progress, Road, American Economic Review, CBB, Digital currency, Agur, European Commission, International Settlement, Constraint, Money, Community business development corporation, City, Equivalence, Eligibility, Ministry of Finance, Report, Control, Civil service commission, EUR, Uncertainty, Eastern Caribbean Central Bank, Abadi, Rest, Reproduction, Fintech, IMF, Federal Reserve, LCR, Data
Key Points: 

    SEALSQ Announces Launch Date of Revolutionary Hybrid Payment & Utility Token, SEALCOIN

    Retrieved on: 
    Friday, April 5, 2024
    MVP, M2M, Nifedipine, Digital, POC, Utility, Semiconductor, LAES, Ecosystem, PKI, Post-quantum cryptography, Cryptocurrency

    SEALSQ Corp ("SEALSQ" or "Company") (NASDAQ: LAES), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products, announces the launch date of SEALCOIN as a Hybrid Payment & Utility Token for its Decentralized Physical Infrastructure Network (DePIN).

    Key Points: 
    • SEALSQ Corp ("SEALSQ" or "Company") (NASDAQ: LAES), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products, announces the launch date of SEALCOIN as a Hybrid Payment & Utility Token for its Decentralized Physical Infrastructure Network (DePIN).
    • The SEALCOIN platform is expected to launch in the fourth quarter of 2024, followed by Token issuance and a proposed listing of SEALCOIN on a digital exchange.
    • SEALCOIN Platform Launch in Q4 2024: The launch of the SEALCOIN platform is expected to take place in October 2024.
    • Token Issuance & Proposed Digital Exchange Listing: Following the launch of the SEALCOIN platform, SEALSQ will proceed with Token Issuance and subsequently list SEALCOIN on a digital exchange .

    Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

    Retrieved on: 
    Wednesday, April 3, 2024
    Medical device, Annual report, ARG1, Documentation, Biotechnology, Sarcoidosis, Partnership, Patient, Scientific Research Publishing, USP7, Ethics, SPO, Biomarker, Research, Health care, Conception, Cancer, Messenger, POC, PLN, Biology, Royal, MHRA, Polish, Clinical trial, Safety, MOC, Phase, ARG2, Food, FDA, SMART, CDA, Pharmaceutical industry

    We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.

    Key Points: 
    • We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.
    • In 2023, our focus was also on preparing for a Phase II clinical trial for OATD 01, Molecure's flagship clinical programme.
    • We are very pleased to report that the first patient has started dosing in a clinical trial at a clinical site in the UK.
    • The Company plans to obtain further grants for projects within the framework of the pipeline developed so far.

    Foresight: Eye-Net Collaborates with Leading Japanese Insurance Company Aiming to Reduce Accident Rate Through Connected Dashcams

    Retrieved on: 
    Monday, April 1, 2024
    Dashcam, Insurance, Accident, POC, Safety, Fault

    Ness Ziona, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), an innovator in automotive vision systems, announced today that its wholly owned subsidiary, Eye-Net Mobile Ltd. (“Eye-Net”), has signed a three-way agreement for a proof-of-concept (POC) project with leading Japanese technology and insurance companies to assess the integration benefits of Eye-Net’s technology with dashboard cameras (dashcams) manufactured by the technology company. This strategic collaboration aims to empower drivers with tools that prevent accidents, to reduce insurance costs and to improve road safety.

    Key Points: 
    • This strategic collaboration aims to empower drivers with tools that prevent accidents, to reduce insurance costs and to improve road safety.
    • The technology company plans to evaluate, and potentially integrate, Eye-Net’s technology into its dashcams.
    • Dashcams serve as unbiased observers, recording live footage of the road and anything that occurs within its field of view.
    • Looking ahead, insurance companies may potentially offer discounted premiums as an incentive for customers who use connected dashcams equipped with Eye-Net’s advanced technology.

    Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update

    Retrieved on: 
    Monday, April 1, 2024
    Blood pressure, EEG, Epilepsy, Bradycardia, Trevena, Rat, Neuropathic pain, Seizure, Central nervous system, Patient, CNS, TMS, Hospital, Sale, Chronic pain, NIH, IND, POC, Safety, Astrocyte, Status epilepticus, Neuroinflammation, Pharmaceutical industry

    CHESTERBROOK, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter ended December 31, 2023 and provided an overview of its recent operational highlights.

    Key Points: 
    • Given performance to date, we are reducing commercial support and reviewing alternatives for OLINVYK to preserve capital,” said Carrie Bourdow, President and CEO of Trevena.
    • OLINVYK will remain available for purchase by customers, who can continue to order the product through their normal channels.
    • In a review of safety and tolerability across both studies, TRV045 was well tolerated with results generally consistent with prior first-in-human studies.
    • For the fourth quarter of 2023, the Company reported a net loss attributable to common stockholders of $16.5 million, or $1.06 per share, compared to $7.0 million, or $0.73 per share in the fourth quarter of 2022.

    Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

    Retrieved on: 
    Tuesday, March 26, 2024
    Diagnosis, Research, Brain, Geographic atrophy, Disease, RWE, International, Paratriathlon, Patient, ARCHER, G&A, Pivotal, EMA, Meta-analysis, Eye, European Medicines Agency, Medicine, Visual acuity, Immunoglobulin therapy, GBS, Facial muscles, Clinical trial, POC, Safety, Pharmacokinetics, Investment, SAD, FDA, BLA, AFL, CAD, Food, Pharmaceutical industry

    BRISBANE, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported fourth quarter and full year 2023 financial results.

    Key Points: 
    • Finally, we anticipate clinical proof-of-concept data from our novel oral inhibitor ANX1502 later in the year.
    • ANX005 in GBS: First-in-class monoclonal antibody designed to block C1q and the entire classical complement pathway in both the body and the brain.
    • ANX005 in GBS: Topline data from pivotal, randomized, placebo-controlled Phase 3 trial expected in the second quarter of 2024.
    • Cash and operating runway: Cash and cash equivalents and short-term investments were $259.7 million as of December 31, 2023.

    StartupOS Announces Generative AI Accelerator Program to Scale Early-Stage Startups and Boost Enterprise Collaboration

    Retrieved on: 
    Tuesday, April 9, 2024
    Data Management, Security, Apps, Applications, Technology, Other Technology, Software, Artificial Intelligence, Health, Risk management, Growth, Mentorship, Communication, Partnership, Health care, AI, Fintech, Generative, Investment, POC, Public sector, Business operations, Sales

    StartupOS , a leader in StartupTech, today announced its first Accelerator Program focused on generative AI.

    Key Points: 
    • StartupOS , a leader in StartupTech, today announced its first Accelerator Program focused on generative AI.
    • The program is designed to accelerate early-stage startups and connect them with emerging enterprises, providing a unique platform for collaboration and growth.
    • Startups accepted into the Generative AI Accelerator Program will gain access to the StartupOS platform, which provides access to essential founder tools, proven mentors, personalized guidance, and partner solutions.
    • To learn more about the Generative AI Accelerator Program, how to get involved as a startup, or how to sponsor a demo day as an enterprise, visit https://startupos.com/events/ .

    C2Sense® and Princeton BioMeditech Receive Second Award from NIH RADx® Tech High Performance Program for Digitally Connected, At-Home Diagnostic Reader and Multiplex COVID-19/Flu A&B Rapid Test

    Retrieved on: 
    Tuesday, April 9, 2024
    Medical imaging, ACME, Halo, Human services, SARS-CoV-2, NIH, Acceleration, Clinical trial, National Institutes of Health, POC, BBC, Omicron, Biological engineering, Bangladesh Technical Education Board, Federal, Health department, PBM, Princeton University

    The companies are currently planning their upcoming clinical trial, regulatory submission, and transfer to manufacture.

    Key Points: 
    • The companies are currently planning their upcoming clinical trial, regulatory submission, and transfer to manufacture.
    • "After rigorous testing and intensive data collection, Halo®, used in conjunction with the PBM multiplex rapid test, continues to demonstrate outstanding sensitivity and reliability," said Jason Cox, Ph.D., CEO at C2Sense.
    • "Powered by our latest algorithm release, the price vs. performance of our Halo reader is unparalleled."
    • As always, we remain committed to providing our customers with the best possible solution for at-home testing," added Cox.

    Communication Test and Measurement Market worth $14.9 billion by 2029 - Exclusive Report by MarketsandMarkets™

    Retrieved on: 
    Monday, April 8, 2024
    Viavi Solutions, LitePoint, POC, Telecom, Telecommunications, Consultant, MIMO, Lab, Rohde & Schwarz, BERT, Measurement, Anomaly, IEEE 802.11be, NetScout Systems, Keysight, FR3, ROI, OTA, Distortion, Communication, RF, Radio frequency, Smartphone, Growth, MediaTek, Spirent, FR1, Research and development, Hertz, Hardware

    In the dynamic landscape of the Communication Test and Measurement Market, an array of specialized software plays a pivotal role in ensuring the seamless functionality and robust performance of communication networks.

    Key Points: 
    • In the dynamic landscape of the Communication Test and Measurement Market, an array of specialized software plays a pivotal role in ensuring the seamless functionality and robust performance of communication networks.
    • To determine, segment, and forecast the global Communication Test and Measurement Market based on offering, test solution, type of test, end user, and region in terms of value.
    • To analyze the industry trends, patents, and innovations related to the Communication Test and Measurement Market.
    • To analyze the opportunities for stakeholders by identifying the high-growth segments of the Communication Test and Measurement Market.

    Communication Test and Measurement Market worth $14.9 billion by 2029 - Exclusive Report by MarketsandMarkets™

    Retrieved on: 
    Monday, April 8, 2024
    Viavi Solutions, LitePoint, POC, Telecom, Telecommunications, Consultant, MIMO, Lab, Rohde & Schwarz, BERT, Measurement, Anomaly, IEEE 802.11be, NetScout Systems, Keysight, FR3, ROI, OTA, Distortion, Communication, RF, Radio frequency, Smartphone, Growth, MediaTek, Spirent, FR1, Research and development, Hertz, Hardware

    In the dynamic landscape of the Communication Test and Measurement Market, an array of specialized software plays a pivotal role in ensuring the seamless functionality and robust performance of communication networks.

    Key Points: 
    • In the dynamic landscape of the Communication Test and Measurement Market, an array of specialized software plays a pivotal role in ensuring the seamless functionality and robust performance of communication networks.
    • To determine, segment, and forecast the global Communication Test and Measurement Market based on offering, test solution, type of test, end user, and region in terms of value.
    • To analyze the industry trends, patents, and innovations related to the Communication Test and Measurement Market.
    • To analyze the opportunities for stakeholders by identifying the high-growth segments of the Communication Test and Measurement Market.